Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales

Novartis AG (SIX: NOVN) reported weaker-than-expected first-quarter 2026 earnings, reflecting mounting pressure from generic drug competition and rising research costs. The Swiss pharmaceutical giant posted core earnings per share (EPS) of $1.99 for the quarter ending March 31, missing analyst forecasts of $2.10 and declining from $2.28 recorded in the same period last year.

Novartis’ quarterly results highlight the growing impact of generics in the U.S. pharmaceutical market, a critical revenue driver for the company. Net sales slipped 1% year-over-year to $13.11 billion, with management citing “U.S. generic erosion” as a key factor behind the decline. The company has been navigating increased competition after losing patent exclusivity in 2025 for three major drugs: Entresto, Promacta, and Tasigna.

Higher research and development (R&D) spending also weighed on profitability, as Novartis continues to invest heavily in its drug pipeline. Despite the earnings miss, CEO Vas Narasimhan emphasized that the impact of generics was anticipated and reiterated confidence in the company’s long-term growth strategy. He pointed to strong pipeline momentum and upcoming clinical trial results expected in the second half of 2026, which could potentially support an improved growth outlook.

Novartis maintained its full-year guidance, projecting low single-digit growth in net sales and a slight decline in core operating income. The company remains focused on innovation and pipeline expansion to offset revenue losses from patent expirations and strengthen its competitive position in the global pharmaceutical industry.

Investors closely monitoring pharma stocks and earnings trends will likely watch how Novartis adapts to ongoing generic competition while leveraging new drug developments to drive future growth.